Constellation Software (CSU.TO) — Post Q1 2026 Valuation
Price (May 13, 2026)
Fair Value (Prob-Weighted)
TTM FCFA2S
Market-Implied Growth
Q1 2026 — Latest earnings (reported May 12, 2026)
| Line item | Q1'26 | Q1'25 | YoY |
|---|---|---|---|
| Revenue | $3,181M | $2,654M | +20% |
| Organic growth (nominal) | 6% | 0.3% | — |
| Organic growth (constant currency) | 2% | — | — |
| Net income (common) | $367M | $136M | +170% |
| Diluted EPS | $17.32 | $6.41 | +170% |
| Cash flow from operations | $897M | $827M | +9% |
| FCFA2S | $733M | $510M | +44% |
| Maintenance and recurring revenue | $2,444M | $1,996M | +22% |
| Acquisitions (cash + deferred) | $809M | — | — |
| EPS vs consensus | +8.3% | — | — |
Why the stock is down 53%
Three concurrent narrative shocks, none operational:
- AI disruption fear. "Vibe-coding" thesis — generative AI lowers entry barriers in vertical software, threatens switching-cost moats. BMO flagged AI as a valuation headwind in late 2025.
- Founder departure. Mark Leonard resigned November 2025 due to a serious health condition. Mark Miller (former COO) installed as CEO. Capital-allocation continuity question.
- Multiple compression across acquisitive compounders. Sector rotation away from "compounders" toward AI direct beneficiaries.
Operating performance hasn't deteriorated meaningfully — CSU delivered 15% revenue and 21% adjusted EPS growth in 2025. The 53% decline is overwhelmingly multiple compression.
Owner economics
CSU pays bonuses in cash, not stock; executives must then buy CSU shares in the open market with after-tax proceeds. SBC drag is effectively zero. FCFA2S is a clean proxy for owner FCF — no subtraction needed. This is rare and a material positive vs typical SaaS comps.
| Owner FCF metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| FCFA2S ($M) | ~1,906 | 1,683 | 1,472 | 1,160 |
| YoY growth | — | +14% | +27% | — |
| FCFA2S/share (USD) | ~$90 | ~$79 | ~$69 | ~$55 |
| FCFA2S/share (CAD) | ~$122 | ~$108 | ~$94 | ~$75 |
Current P/FCFA2S: CAD 2,397 / CAD 122 = 19.7x — near a 10-year low.
Three-scenario DCF
Cost of equity: Rf (Canada 10Y) 3.5% + beta 0.90 × ERP 5.5% = 8.4%. CSU has more stable cash flows than the software industry average; beta below 1.0 is appropriate (TradingView reports 0.80).
| Scenario | Prob. | 10-yr FCFA2S CAGR | Terminal P/FCFA2S | NPV (CAD) |
|---|---|---|---|---|
| Bear — AI thesis right; organic stalls; ROIC erodes | 25% | 6% | 14x | 1,750 |
| Base — patient compounder; 12-15% growth reverts | 50% | 13% | 22x | 3,400 |
| Bull — AI accretive; private mults fall; bigger deals at 20%+ IRR | 25% | 18% | 28x | 5,400 |
Probability-weighted fair value: CAD 3,488 per share. Implied upside from CAD 2,397: +46%.
Reverse DCF sanity check
At CAD 2,397 with TTM FCFA2S/share approximately CAD 122 and cost of equity 8.4%, the perpetuity formula 1/(k–g) = P/FCF solves for:
Implied long-term FCFA2S growth = 3.3%
For context, CSU has compounded FCF at 20%+ for two decades and printed +14% YoY FCFA2S growth in FY 2025 with capital deployment ahead of schedule in Q1'26. Market is pricing roughly inflation-only growth into perpetuity. That bar is low.
Peer comparison
All figures USD unless noted; data as of mid-May 2026.
| Metric | CSU | ROP | TYL | TOI.V | LMN.V |
|---|---|---|---|---|---|
| Market cap | $37.3B | $34.7B | $12.6B | CAD 7.2B | CAD 5.3B |
| Enterprise value | ~$39.5B | $44.7B | $13.9B | CAD 8.5B | CAD 5.3B |
| TTM revenue | $12.15B | $8.11B | $2.33B | CAD 2.50B | CAD 1.05B |
| EV/Revenue | 3.3x | 5.5x | 6.0x | 3.4x | 5.0x |
| EV/EBITDA (TTM) | ~13-14x | 13.0x | 26.1x | 40.3x* | 12.7x |
| P/FCF or EV/FCF | 19.7x | 14.0x | 22.1x | 13.6x | 15.6x |
| Trailing P/E | ~50x (noisy) | 21.4x | 47.0x | 113x* | 31.9x |
| Forward P/E | n/a | 15.9x | 27.0x | 24.0x | 15.9x |
| Organic growth (recent) | 2-6% | 4-5% | 7-9% | 4-6% | -2 to +1% |
| ROIC | 18-20% | 13-15% | 9% | 12% | 19% |
| YoY stock return | -53% | -22% | -42% | -37% | -53% |
| Down from 52w high | -55% | -32% | -42% | -37% | -63% |
Read-across
- vs Roper (closest US-listed comp): CSU cheaper on EV/Revenue (3.3x vs 5.5x), comparable on EV/EBITDA, more expensive on P/FCF (19.7x vs 14.0x). CSU's higher ROIC (18-20% vs 13-15%) and longer compounding history justify some premium. ROP grew FY25 revenue 12% with 5% organic; CSU 15%/4%.
- vs Tyler: TYL at 27x forward earnings even after a 42% drawdown. CSU at half that multiple with better ROIC, comparable organic growth, and bigger M&A optionality. TYL is the most expensive in the cohort; CSU has more cushion.
- vs Topicus and Lumine (the spins): TOI at 13.6x P/FCF is the cheapest pure-play VMS aggregator. LMN at 15.6x is close. If you believe in the model, the spins are cheaper than the parent. CSU trades at a 30-40% premium to TOI/LMN P/FCF — historically that gap averaged 20-30%, so CSU is at the top of the range. Justified by track record, scale, and Vela/Harris/Volaris diversification.
Key risks (bear case detail)
- AI thesis is structurally correct. Vela (industrial/telecom legacy) and parts of Perseus are most exposed. Harris, Volaris, and Topicus are largely AI-resistant, covering approximately 70% of revenues. Even in a hostile-AI world, 70% of revenue is defensible.
- Hurdle rate compression. Historical 25%+ IRRs slipping toward 18-20% as deal sizes grow. Asseco Poland minority stake ($321M, Q4'25) was a departure from the pure VMS playbook.
- Organic growth. Q1'26 6% nominal but 2% constant-currency. CFO Miller openly pushing for better. If 2% is the new normal, base-case FCFA2S CAGR drops toward 8-10%.
- Margin drag from acquisition cohorts. Q1'26 margins down materially due to acquired-company drag. Management says expected; if it doesn't reverse, base case at risk.
- Leonard succession. Capital-allocation discipline relies on culture, not one person. Soft risk; warrants monitoring.
Conclusion
| Current price | CAD 2,397 |
| Probability-weighted fair value | CAD 3,488 |
| Implied upside | +46% |
| Reverse-DCF implied growth (market) | 3.3% |
| Historical FCF CAGR | 20%+ |
Rating: BUY with conviction caveat. CSU is being priced as if FCFA2S grows at inflation forever and ROIC compresses materially. Even the bear case (CAD 1,750) is only 27% below current price. Base case offers approximately 42% upside; bull case approximately 125%.
Alternative expression
Topicus (TOI.V) at 13.6x P/FCF is the cleanest pure-play exposure if the goal is the same thesis with less aggregation risk and more European-VMS leverage. CSU offers diversification across all seven operating groups plus the Asseco optionality.
Options consideration (single-leg only)
CSU options are illiquid on TSX. Direct equity is the practical implementation. If options are accessible via OTC ADR (CNSWF), avoid near-dated calls into next earnings (Q2 reports Aug 7) due to IV crush; LEAPS extending past Q1'27 would be the cleanest directional expression.
Catalysts to watch
- Aug 7, 2026: Q2 earnings — does constant-currency organic growth recover to 3-4%?
- Continued capital deployment pace ($697M Q1'26 was ahead of schedule)
- Any Asseco-style large minority stake suggesting a "buy" of a larger consolidator
- AI integration disclosures from operating group leaders (Volaris, Harris)
No redactions applied.
Published via wiis. Originals are encrypted at rest; this page reflects the redacted version. report abuse.
Discussion
No comments yet.